Survodutide’s dual glucagon/GLP-1 receptor agonism reduces hepatic steatosis and circulating IL-1β levels in phase III NASH trials, while oral GLP-1 RAs like orforglipron circumvent injection barriers without compromising anti-inflammatory efficacy [61,62]. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatohepatitis.